Home

Personalizing Relapsed/Refractory DLBCL With Bispecific Antibody Therapy

A Case-Based Discussion CME/CNE/CPE

Orange County Convention Center

Friday, December 5, 2025 | 3:30 PM - 5:00 PM TZ

Supported by an independent educational grant from AbbVie and Genmab US, Inc.

overview

Join us for a unique interactive program designed to enhance your clinical approach to refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL). Our expert faculty, including a patient advocate from the Lymphoma Coalition, will utilize real-world case studies to highlight best practices in personalizing DLBCL care with bispecific antibodies. Don’t miss this opportunity to stay updated on advancements in R/R DLBCL treatment. Reserve your spot today!

Friday Satellite Symposium on Hematology, preceding the 67th ASH Annual Meeting and Exposition.

Enhance Your Experience With MedChallenge!

This event features MedChallenge, a new feature from Medscape that allows you to go head-to-head against your peers in a series of medical questions. Earn points, deepen your knowledge, and fight for the top spot on the leaderboard!

Enhance Your Virtual Experience With Backstage Pass! Backstage Pass provides an intimate virtual session where you can interact with faculty, address case-based questions, and facilitate relationship building.

*Video encouraged*

TARGET AUDIENCE

This educational activity is intended for an audience of hematologists/oncologists, physician assistants, nurse practitioners, nurses, pharmacists, and other members of the oncology care team in the United States.

GOAL STATEMENT

The goal of this activity is for learners to be better able to incorporate bispecific antibodies into clinical practice and individualize care for R/R DLBCL.

LEARNING OBJECTIVES

[bold]Upon completion of this activity, participants will:[/bold] Have increased knowledge regarding the[LIST][ITEM]Identification of key clinical trial data for bispecific antibodies in R/R DLBCL[ITEM]Definition of selection criteria for bispecific antibody therapy in the R/R DLBCL setting[/LIST]Have greater competence related to[LIST][ITEM]Implementing practical management strategies to optimize the use of bispecific antibodies in R/R DLBCL[/LIST]Demonstrate greater confidence in their ability to[LIST][ITEM]Integrate patient-centered care strategies for R/R DLBCL with bispecific antibodies

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[title]For Physicians[/title] [text]Medscape, LLC designates this live activity for a maximum of 1.50 [bold][italic]AMA PRA Category 1 Credit(s)[/italic][super]TM[/super][/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[/text] [break] [title]For Nurses[/title] [text]Awarded up to 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs.[/text] [break] [title]For Pharmacists[/title] [text]Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-25-190-L01-P).[/text]